Loading…
BridgeBio Oncology Therapeutics, Inc. is projected to rise to $8.70 by 2027, a +20% move from its current price of $7.26. BBOT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 6/10/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jun 11 | $7.06 | $7.26 | $7.46 | -0.01% |
| Jun 12 | $6.98 | $7.26 | $7.55 | -0.02% |
| Jun 13 | $6.92 | $7.26 | $7.62 | -0.03% |
| Jun 14 | $6.86 | $7.26 | $7.67 | -0.04% |
| Jun 15 | $6.82 | $7.26 | $7.72 | -0.05% |
| Jun 16 | $6.78 | $7.26 | $7.77 | -0.06% |
| Jun 17 | $6.74 | $7.25 | $7.81 | -0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.74 | $7.25 | $7.81 | -0.07% |
| Week 2 | $6.53 | $7.25 | $8.04 | -0.14% |
| Week 3 | $6.38 | $7.24 | $8.23 | -0.21% |
| Week 4 | $6.25 | $7.24 | $8.39 | -0.28% |
| Week 5 | $6.14 | $7.23 | $8.53 | -0.35% |
| Week 6 | $6.04 | $7.23 | $8.66 | -0.42% |
| Week 7 | $5.95 | $7.22 | $8.78 | -0.49% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors.
The company was incorporated in 2016 and is headquartered in South San Francisco, California.
BBOT currently trades at $7.26 and has a market capitalization of $581.58M, with a ranking of 2852. This places the stock in a mid-cap tier with a defined price level near the $7s region.
The 30-day price range runs from $6.04 to $8.72, and the near-term technical picture shows bearish sentiment. The price is below the SMA50 of $8.61 and the SMA200 of $10.63, with a nearby support at $7.66 and resistance at $9.11.
Forecasts indicate a bullish longer-term trajectory, with the average price rising from $7.26 in 2026 to higher levels over time: 2027 average $8.70; 2030 average $10.77; 2040 average $17.96; 2050 average $35.18. The forecast also shows projected maxes such as $9.60 in 2026, $11.62 in 2027, and $65.50 by 2050, with long-run ROI reaching 384.5% by 2050.
Overall, the outlook suggests upside over the extended horizon, but near-term momentum remains under pressure given the current price action and volatility.
A major floor 7.3% below — a decisive break under it would weaken the trend.
Support has flipped 5.5% overhead — reclaiming it would be bullish.
The nearest ceiling, 25.5% above — a clean break opens room to run.
A major ceiling 72.2% above — clearing it would confirm fresh momentum.
Key BBOT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BBOT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.02 | Sell | $8.03 | Sell |
| MA 10 | $8.34 | Sell | $8.22 | Sell |
| MA 20 | $8.42 | Sell | $8.37 | Sell |
| MA 50 | $8.61 | Sell | $8.74 | Sell |
| MA 100 | $9.61 | Sell | $9.40 | Sell |
| MA 200 | $10.63 | Sell | $10.06 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.14 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -133.42 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -11.69 | Sell |
| Bollinger %B (20,2) | 0.07 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.13 | Sell |
| Awesome (5,34) | -0.43 | Sell |
| Ultimate (7,14,28) | 27.16 | Buy |
| Momentum (10) | -0.77 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 7.75 | Sell |
| ADX (14) | 12.67 | Neutral |
| ATR (14) | 0.23 | Info |
The near-term technical picture is bearish, with RSI(14) at 40. This indicates modest downward momentum in the immediate period. The stock is trading below both the SMA50 ($8.61) and the SMA200 ($10.63), suggesting ongoing pressure from shorter- and longer-term moving averages.
Key support sits at $7.66, with a resistance level at $9.11. The 30-day range spans from $6.04 to $8.72, highlighting recent volatility and a tendency to trade within a relatively tight band around the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.26 | $7.26 | $9.60 | 0% | Neutral | |
| $6.89 | $8.70 | $11.62 | +20% | Neutral | |
| $7.96 | $10.33 | $14.32 | +42% | Bullish | |
| $7.77 | $10.32 | $14.73 | +42% | Bullish | |
| $7.94 | $10.77 | $15.75 | +48% | Bullish | |
| $8.28 | $11.44 | $17.09 | +58% | Bullish | |
| $7.56 | $10.63 | $16.19 | +46% | Bullish | |
| $8.19 | $11.70 | $18.13 | +61% | Bullish | |
| $9.62 | $13.97 | $21.99 | +92% | Bullish | |
| $10.20 | $15.04 | $24.04 | +107% | Bullish | |
| $11.38 | $17.96 | $30.54 | +147% | Bullish | |
| $19.80 | $35.18 | $65.50 | +385% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| June 2026 | $7.26 | $7.26 | $8.87 | +0.00% |
| July 2026 | $6.30 | $7.44 | $9.03 | +2.46% |
| August 2026 | $6.05 | $7.19 | $8.83 | -3.29% |
| September 2026 | $6.08 | $7.27 | $9.01 | +1.08% |
| October 2026 | $6.28 | $7.56 | $9.44 | +3.96% |
| November 2026 | $6.26 | $7.56 | $9.51 | +0.02% |
| December 2026 | $6.24 | $7.58 | $9.60 | +0.24% |
Click any year to see its month-by-month BBOT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BBOT to range from $7.26 to $9.60 through 2026. The $7.26 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The BBOT price prediction for 2027 points to an average of $8.70 (low $6.89, high $11.62) — a potential gain of +20% on today's $7.26. A consolidation phase looks the most probable path here.
In 2028, BBOT is projected to trade between $7.96 and $14.32, averaging $10.33 — a potential gain of +42% from today's $7.26. That is up +19% on the projected 2027 average. Momentum favours further upside here.
BridgeBio Oncology Therapeutics, Inc.'s 2029 outlook centres on $10.32, within a $7.77 to $14.73 range. That is 0% versus the projected 2028 average. That marks a +42% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, BBOT could reach as high as $15.75, with a base case around $10.77 and support toward $7.94 — roughly +48% from $7.26. Momentum favours further upside here.
Expect BBOT to range from $8.28 to $17.09 through 2031. The $11.44 average target implies a +58% move from current prices. That is up +6% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The BBOT price prediction for 2032 points to an average of $10.63 (low $7.56, high $16.19) — a potential gain of +46% on today's $7.26. Momentum favours further upside here.
In 2033, BBOT is projected to trade between $8.19 and $18.13, averaging $11.70 — a potential gain of +61% from today's $7.26. That is up +10% on the projected 2032 average. Buyers look set to stay in control over this stretch.
BridgeBio Oncology Therapeutics, Inc.'s 2034 outlook centres on $13.97, within a $9.62 to $21.99 range. That is up +19% on the projected 2033 average. That marks a +92% change versus current levels. Momentum favours further upside here.
By 2035, BBOT could reach as high as $24.04, with a base case around $15.04 and support toward $10.20 — roughly +107% from $7.26. Buyers look set to stay in control over this stretch.
Expect BBOT to range from $11.38 to $30.54 through 2040. The $17.96 average target implies a +147% move from current prices. That is up +19% on the projected 2035 average. Momentum favours further upside here.
The BBOT price prediction for 2050 points to an average of $35.18 (low $19.80, high $65.50) — a potential gain of +385% on today's $7.26. Buyers look set to stay in control over this stretch.
Investing $1,000 in BBOT today (≈ 137.741047 BBOT) could be worth
$4,845.07
+$3,845.07 (+385%) by 2050 · US Dollar
Based on the average projected BBOT price of $35.18 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BBOTwould be worth at today's price.
$1,000 invested in BBOT on Jun 9, 2025 (≈ 91.911764 BBOT) would be worth
$667.28
-$332.72 (-33.3%) today · 0.67× · US Dollar
Based on a BBOT entry price of $10.88 vs. today's $7.26.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.55 | $849.12 | -15.1% |
| 1 month ago | $7.66 | $947.78 | -5.2% |
| 3 months ago | $10.19 | $712.46 | -28.8% |
| 6 months ago | $12.88 | $563.66 | -43.6% |
| 1 year ago | $10.88 | $667.28 | -33.3% |
| All time (2.3y) ago | $10.19 | $712.46 | -28.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BBOT forecast.
Our base-case forecast reaches $15.00 around 2035.
Implied market cap at $15.00: $1.2B
The multi-year forecast points to a bullish trend from 2027 onward, with the average price rising through the period and a growing ROI. In 2027, the average is predicted to be $8.70 with a max of $11.62 and an ROI of 19.8%. By 2030, the average is $10.77 with a max of $15.75 and an ROI of 48.3%.
The 2040 forecast shows an average of $17.96 with a max of $30.54 and an ROI of 147.4%. By 2050, the average is projected at $35.18, the max at $65.50, and the ROI at 384.5%. The sentiment remains BULLISH in 2030 and beyond.
These are estimates, not guarantees, and depend on a range of factors not limited to product success, regulatory outcomes, and market dynamics. The outlook should be interpreted as a directional guide rather than a promise of future results.
Tap a question to reveal the answer.
2030 forecast: min $7.94, avg $10.77, max $15.75; ROI 48.3%; sentiment BULLISH.
Forecasts show a bullish trajectory with average prices rising to $35.18 by 2050 and a max of $65.50; ROI 384.5% by 2050; sentiment BULLISH.
Yes. The 2030 forecast max price is $15.75.
Current price is $7.26 and market cap is $581.58M.
2050 forecast: avg $35.18, max $65.50; ROI 384.5%; sentiment BULLISH.
BridgeBio Oncology Therapeutics, Inc. Community Discussion
0Share your BridgeBio Oncology Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.